Simulations Plus Inc
Затворен
СекторЗдравеопазване
18.42 -0.05
Преглед
Промяна на цената на акция
24 ч
Минимум
18.41
Максимум
18.42
Приходи | -960K 3.6M |
|---|---|
Продажби | -2.4M 22M |
P/E Средно за сектора | 46.075 56.597 |
EPS | 0.3 |
Марж на печалбата | 16.335 |
Служители | 212 |
EBITDA | -6.3M 1.1M |
Пазарна капитализация | 1.6M 373M |
|---|---|
Предишно отваряне | 18.47 |
Предишно затваряне | 18.42 |
Настроения в новините
By Acuity
50%
50%
146 / 339 Класиране в Healthcare
Simulations Plus Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Simulations Plus Inc Прогноза
Настроение
By Acuity
146 / 339 Класиране в Здравеопазване
Настроения в новините
Neutral
Волатилност
Под средното
Обем новини (RCV)
Под средното
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
